Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
Vivos Therapeutics, Inc. (VVOS)
Company Research
Source: GlobeNewswire
LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced first time, peer-reviewed published data confirming that the Vivos DNA (Daytime-Nighttime Appliance®) is both safe and efficacious in treating children suffering from OSA. Results from a multicenter clinical trial, now published in the European Journal of Pediatrics, represent a significant milestone in the fight against one of the most underdiagnosed and undertreated pediatric health conditions. The DNA appliance is part of Vivos’ Complete Airway Repositioning and Expansion (“C.A.R.E.”) line of devices. According to recent published research estimates, up to 20.4% of U.S. children — as many as 10 million — are living with p
Show less
Read more
Impact Snapshot
Event Time:
VVOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VVOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VVOS alerts
High impacting Vivos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VVOS
News
- Vivos Therapeutics (NASDAQ:VVOS) had its price target lowered by analysts at Ascendiant Capital Markets from $6.50 to $5.50. They now have a "buy" rating on the stock.MarketBeat
- Vivos Therapeutics (NASDAQ:VVOS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- Vivos Therapeutics Inc (VVOS) Q3 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ... [Yahoo! Finance]Yahoo! Finance
- Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 [Yahoo! Finance]Yahoo! Finance
- Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025GlobeNewswire
VVOS
Earnings
- 11/19/25 - Beat
VVOS
Sec Filings
- 12/5/25 - Form 8-K
- 11/19/25 - Form 8-K
- 11/19/25 - Form 10-Q
- VVOS's page on the SEC website